154. SGLT2, Mindfulness, Pill on a String episode artwork

EPISODE · Nov 15, 2020 · 24 MIN

154. SGLT2, Mindfulness, Pill on a String

from Questioning Medicine · host Questioning Medicine

https://www.acpjournals.org/doi/10.7326/M20-2470 Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical GuidelineFREEWhich is as the artciel suggest in a sypnopsis of the 2020 ADA guidelines metformin is still universal fist line but now the guideline says The choice of agent to add to metformin therapy should be individualized on the basis of patient characteristics, preferences, and drug-specific effects. The big rec from this paper isAmong patients with type 2 diabetes who have established ASCVD or established kidney disease, or heart failure, a sodium–glucose cotransporter-2 (SGLT2) inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA) with demonstrated cardiovascular disease benefit is recommended (Grade A recommendation). they go on to say maybe one of the key lines--------The addition of these medications should be considered independent from HbA1c level in this patient population. You might remember dapaggliflozin – the article last year that I said was one of the top articles of the year because it changed how we practice for both diabetes and heart failure!! Well now---I give you--- https://www.nejm.org/doi/10.1056/NEJMoa2022190 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure in the NEJM EMPEROR-Reduced trial recently out which looked to see if empagliclozin could join dapagliflozin for risk reduction in heart failure!!This was a double-blind, randomized, placebo-controlled, using empagliflozin (10 mg daily) At a mean follow-up of 16 months, patients receiving empagliflozin had a lower risk for the primary endpoint of cardiovascular death or hospitalization for worsening HF than placebo recipients with a shocking NNT of 20 although this was mainly driven by heart failure hospitalizations these numbers are similar to dapagliflozin -- (19.4% vs. 24.7%). –AND THIS was INDEPENDENT OF DIABETIC DIAGNOSIS!! AND when you looked at the change in A1C at the end of the trial—there was no difference, just maybe these SGLT2 inhibitors really are people drugs, not diabetic drugs which has to make everyone question the relevance of the surrogate marker we use for diabetes, A1C. not to go on too much of a rant but if we look at A1C and say this is the standard by which all drugs should be measured and some drugs DO NOT CHANGE THE A1C or at least not with any clinical significance but they do prevent death, MI and hospisitliations while other drugs dont change any of the hard outcomes but they change the A1C we have to say maybe just maybe A1C is not the marker we should care about. and as excited as I am abou the rush of evidence around SGLT2 inhibitors. Sadly the best medication is likely still prevention, with healthy lifestyle- these drugs are still around $500 a month so we are talking at least 6grand a year for a drug that 95 out of 100 people will never benefit from. Which means we are talking roughly 120,000$ per event saved! So I grant you this is a really impressive article and empagliflozin is now joining dapagliflozin to prevent heart failure hospitalistizations, and I still think the SGLT-2 inhibitors are quickly becoming king of the castle for diabetes treatment—I also think they will never truly take the thrown till they are $4 a month like metformin. next article And while talking guidelines Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: The Diagnosis and Management of Hypertension in the Primary Care SettingFREE Also in annals of internal medicine but had a couple interesting or new recommendations like we suggest using attended or unattended, fully automated blood pressure measurement. A fully automated BP programmed to wait 5 minutes and recod the average of threee measurements separated by at least 30 seconds there goal bp is <130unless you are 60yrs old and older then <150but If you are 60yrs and older AND DM then <140 with any of the main medication- ACE, ARB, CC, thiazide and if they are on 3 or more of these medications then it is resistant and give spironolactone nothing too shocking in this paper but just a good refresher and something to keep in mind, and speaking of keeping in mind!! Seminowicz DA, Burrowes SA, Kearson A, et al. Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes. Pain 2020;161(8):1837-1846. this RCT of almost 100 people recruited mostly white women who had on average about 8 headaches a month and 85% were not on prophylaxis medications pts were enrolled in either mindfulness-based stress reduction classes or stress management for headaches classes. The classes met weekly for 8 weeks, then biweekly for another 8 weeks. Those in the mindfulness classes went from 8 headaches a month down to 5 and those in the stress management classes went down to 7. So there was a much bigger difference in the group randomized to mindfulness classes. You might be saying this is a really small reduction in headaches to only go from 8 to 5 and at 1 year of follow up there was no difference, which is likely because the people stopped doing mindfulness. However I will remind you the treatment we have for headaches is some of the worst in medicine. We pass and prescribe drugs all the time that reduce your month headache burdon by 1 or 2 and part of what makes treating headaches so difficult is the mental aspect which is why placebo does so well in most trials. a paperVerhagen AP, Damen L, Berger MY, Passchier J, Koes BW. Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review. Fam Pract 2010;27(2):151-165.which was a systematic review looking at prophylaxis treatment of tension headaches. They looked at antidepressants, muscle relaxants, benzodiazepines, or vasodilatorsand found There is no evidence -- or only poor quality -- that any of these prophylactic agents are effective for tension-type headaches so keep in mind while a mindfulness course might night sound like a good headache treatment plan, it might be the best thing we have….. effective as prophylaxis for patients with frequent tension headaches? and while this podcast might be torture to your eardrums this last article should fall under torture and stupid- Fitzgerald RC, di Pietro M, O'Donovan M, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet 2020;396(10247):333-344. which was a nonblinded trial that looked to see if swallowing a special sponge to sample esophageal epithelial cells for biomarker testing identify patients with Barrett's esophagus in primary care settings?basically is it possible to diagnose BE in the outpatient primary care setting. the authors enrolled patients at least 50 years old who had received H2 receptor antagonists or proton pump inhibitors for at least 6 months in the previous year. The researchers randomized the patients to receive usual care which was continue acid surpression and maybe an EGD if the provider felt like it OR they would undergo this toture office-based screening. In total around 1500 patients underwent this torture procedure. before I tell you what the procedure was I will say that 89% of the patients felt the procedure was tolerable but while getting a foley cath is technically tolerable I would want one and while getting a rectal tube is tolerable, no….no thank you. soo the intervention consisted of swallowing a capsule containing a sponge attached to a thread. After the patient swallows the capsule, the nurse yanks on the thread and pulls out the sponge and sends it for analysis looking at a couple markers found in the gut to tell us if the patient had barrients esophogus. YOU SWALLOWED A PILL THEN JUST A NURSE PULL IT BACK OUT OF YOUR FROM WITH A STRING---THIS IS A PILL ON A STRING!!!!! The results did show that who that had this string torture procedure were diagnosed more often, twice as often. The usual care was diagnosed with BE around 1% and the tampon string pill people were diagnosed with it a whopping 2% of the time. You were 2x as likely to be diagnosed with BE!!!2 TIME AS LIKELY!!!BUT we always have to ask whats the outcome… BE means nothing without cancer. afib means nothing without a stroke. well the rate of BE turning to cancer is RARE- a cohort study titledHvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011;365(15):1375-1383.estimated an annual incidence of esophageal cancer to be LOW, real LOW they say--Barrett's esophagus is a strong risk factor for esophageal adenocarcinoma, but the absolute annual risk, 0.12%, is much lower than the assumed risk of 0.5%, which is the basis for current surveillance guidelines. Data from the current study call into question the rationale for ongoing surveillance in patients who have Barrett's esophagus without dysplasia.

Episode metadata supplied by the publisher feed · Published Nov 15, 2020

https://www.acpjournals.org/doi/10.7326/M20-2470 Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline FREE Which is as the artciel suggest in a sypnopsis of the 2020 ADA guidelines metformin is still universal fist line but now the guideline says The choice of agent to add to metformin therapy should be individualized on the basis of patient characteristics, preferences, and drug-specific effects. The big rec from this paper is Among patients with type 2 diabetes who have established ASCVD or established kidney disease, or heart failure, a sodium–glucose cotransporter-2 (SGLT2) inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA) with demonstrated cardiovascular disease benefit is recommended (Grade A recommendation). they go on to say maybe one of the key lines--------The addition of these medications should be considered independent from HbA1c level in this patient population. You might remember dapaggliflozin – the article last year that I said was one of the top articles of the year because it changed how we practice for both diabetes and heart failure!! Well now---I give you--- https://www.nejm.org/doi/10.1056/NEJMoa2022190 Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure in the NEJM EMPEROR-Reduced trial recently out which looked to see if empagliclozin could join dapagliflozin for risk reduction in heart failure!! This was a double-blind, randomized, placebo-controlled, using empagliflozin (10 mg daily) At a mean follow-up of 16 months, patients receiving empagliflozin had a lower risk for the primary endpoint of cardiovascular death or hospitalization for worsening HF than placebo recipients with a shocking NNT of 20 although this was mainly driven by heart failure hospitalizations these numbers are similar to dapagliflozin -- (19.4% vs. 24.7%). –AND THIS was INDEPENDENT OF DIABETIC DIAGNOSIS!! AND when you looked at the change in A1C at the end of the trial—there was no difference, just maybe these SGLT2 inhibitors really are people drugs, not diabetic drugs which has to make everyone question the relevance of the surrogate marker we use for diabetes, A1C. not to go on too much of a rant but if we look at A1C and say this is the standard by which all drugs should be measured and some drugs DO NOT CHANGE THE A1C or at least not with any clinical significance but they do prevent death, MI and hospisitliations while other drugs dont change any of the hard outcomes but they change the A1C we have to say maybe just maybe A1C is not the marker we should care about. and as excited as I am abou the rush of evidence around SGLT2 inhibitors. Sadly the best medication is likely still prevention, with healthy lifestyle- these drugs are still around $500 a month so we are talking at least 6grand a year for a drug that 95 out of 100 people will never benefit from. Which means we are talking roughly 120,000$ per event saved! So I grant you this is a really impressive article and empagliflozin is now joining dapagliflozin to prevent heart failure hospitalistizations, and I still think the SGLT-2 inhibitors are quickly becoming king of the castle for diabetes treatment—I also think they will never truly take the thrown till they are $4 a month like metformin. next article And while talking guidelines Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: The Diagnosis and Management of Hypertension in the Primary Care Setting FREE Also in annals of internal medicine but had a couple interesting or new recommendations like we suggest using attended or unattended, fully automated blood pressure measurement. A fully automated BP programmed to wait 5 minutes and recod the average of threee measurements separated by at least 30 seconds(continued)

PodParley-generated summary based on available episode metadata and transcript content.

NOW PLAYING

154. SGLT2, Mindfulness, Pill on a String

0:00 24:26

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

The Health Odyssey: Navigating Tomorrow's Medicine Podcast Welcome to 'The Health Odyssey: Navigating Tomorrow's Medicine,' where we embark on an adventurous journey through the ever-evolving world of healthcare. Each episode is like a treasure map, guiding you through the rich tapestry of ancient healing arts mixed with futuristic tech wizardry. We’ll chat about the wild west of health data privacy, the corporate giants reshaping our care, and the mind-bending potential of psychedelics for mental wellness. Think of us as your trusty sidekicks, unraveling the mysteries of modern medicine while keeping it real and relatable. Let’s dive into the stories, the science, and the soul of healthcare, paving the way for a healthier tomorrow. Lynne's Podcast Lynne August MD Dr. A offers her interpretations and applications of Dr. Revici’s profound research at DrRevici.com and the Revici Journal. Dr. Revici was arguably fifty to one hundred years ahead of his time in his application of quantum physics to medical sciences. As a once-aspiring physicist, this alone propelled Dr. A to Dr. Revici. As a physician, she felt compelled, and in some palpable way responsible, to understand Dr. Revici’s ability to control pain and achieve remissions in terminal cancer patients with his non-toxic “guided chemotherapy”, even many cancers that conventional therapy failed to control. Most of the time his questions and solutions were as unprecedented as they were effective. While Dr. Revici was primarily focused on cancer, Dr. A’s research and therapeutics to prevent and treat all chronic and degenerative disease can transform 21st century medicine. Dance Med Spotlight Alyssa Arms We dive into the world of dance medicine and science. Our goal is to provide valuable insights & practical knowledge to established professionals, individuals interested in working with dancers, and the dance community as a whole. Tune in to Dance Med Spotlight for amazing conversations with experts, dance industry professionals, & dance community members. Host: Alyssa Arms Rania Awaad Muslim Central Dr. Rania Awaad M.D., is a Clinical Associate Professor of Psychiatry at the Stanford University School of Medicine where she is the Director of the Stanford Muslim Mental Health & Islamic Psychology Lab as well as Stanford University’s Affiliate Chaplain. In the community, she serves as the Executive Director of Maristan.org, a holistic mental health nonprofit serving Muslim communities, and the Director of The Rahmah Foundation, a non-profit organization dedicated to educating Muslim women and girls. In addition, she is faculty of Islamic Psychology at Cambridge Muslim College and The Islamic Seminary of America.She is also a Senior Fellow for Yaqeen Institute and the Institute of Social Policy and Understanding. Prior to studying medicine, she pursued classical Islamic studies in Damascus, Syria, and holds certifications (ijaza) in the Qur’an, Islamic Law, and other branches of the Islamic Sciences.

Frequently Asked Questions

How long is this episode of Questioning Medicine?

This episode is 24 minutes long.

When was this Questioning Medicine episode published?

This episode was published on November 15, 2020.

What is this episode about?

https://www.acpjournals.org/doi/10.7326/M20-2470 Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical GuidelineFREEWhich is as the...

Can I download this Questioning Medicine episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!